Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06730347 · ClinicalTrials.gov registry record · Phase 2

A Study of Lorigerlimab in Participants With Advanced Solid Tumors

A Phase 2 study of Platinum-resistant Ovarian Cancer and Platinum-Resistant Fallopian Tube Carcinoma, sponsored by MacroGenics.

Recruiting
Registry status
Phase 2
Development phase
60
Enrollment target
16
Study locations

NCT06730347 is a Phase 2 study of Platinum-resistant Ovarian Cancer and Platinum-Resistant Fallopian Tube Carcinoma that is actively recruiting participants, run by MacroGenics. The registered enrollment target is 60 participants, below the 182-participant average among 17 other Platinum-resistant Ovarian Cancer trials with a reported enrollment target (67% lower). The trial reports 16 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06730347, a Phase 2 study of Platinum-resistant Ovarian Cancer and Platinum-Resistant Fallopian Tube Carcinoma, is actively recruiting participants, sponsored by MacroGenics.

RECRUITING
Registry status
Phase 2
Development phase
60 participants
Enrollment target
16
Study locations

Study Summary

Study CP-MGD019-03 is an open-label study of lorigerlimab in participants with platinum-resistant ovarian cancer (PROC) or clear cell gynecologic cancer (CCGC). Approximately 60 participants will be enrolled. The study will assess the efficacy and safety of lorigerlimab in participants with PROC or CCGC. Participants will receive lorigerlimab by intravenous (IV) infusion on Day 1 of every 21-day treatment cycle. Treatment cycles will continue until progression of cancer, unacceptable side effects, withdrawal of consent by the participant, or the study ends. Participants will be monitored closely for side effects by physical exam and routine laboratory tests every cycle. Tumor status will be checked approximately every 9 weeks for the first year, then every 12 weeks for the duration of treatment. Participants will have a safety followup performed within 30 days after treatment discontinuation. Participants who discontinue study treatment for reasons other than progression of cancer, will continue CA-125 and tumor assessments every 12 weeks. Participants who discontinue study treatment for progression of cancer will enter the 6-month survival follow up portion of the study.

Conditions Studied

Platinum-resistant Ovarian Cancer Platinum-Resistant Fallopian Tube Carcinoma Platinum-Resistant Primary Peritoneal Carcinoma Clear Cell Adenocarcinoma of Ovary Clear Cell Adenocarcinoma of Vulva Clear Cell Adenocarcinoma of Vagina Clear Cell Adenocarcinoma of Cervix Clear Cell Adenocarcinoma of Uterus Clear Cell Adenocarcinoma of Fallopian Tube Clear Cell Adenocarcinoma of Peritoneum

Interventions

  • BIOLOGICAL Lorigerlimab

Study Locations (16)

Other

  • Yonsei University Health System Severance Hospital - Seoul
  • Gangnam Severance Hospital - Seoul
  • Korea University Guro Hospital - Seoul
  • Seoul National University Hospital - Seoul
  • Samsung Medical Center - Seoul

Texas

  • Mays Clinic - Houston
  • START San Antonio - San Antonio

California

  • UCLA - Los Angeles

Louisiana

  • Ochsner MD Anderson Cancer Center - New Orleans

Michigan

  • START Midwest - Grand Rapids

Pennsylvania

  • West Penn Allegheny Health - Pittsburgh

Wisconsin

  • Wisconsin Institute Medical Research- UW Cancer Connect - Madison

Ontario

  • Princess Margaret Cancer Center - Toronto

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2025-05-01
Est. Completion 2027-08
Phase Phase 2

Sponsor

MacroGenics

36 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06730347

The ClinicalTrials.gov registry entry for NCT06730347 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 182-participant average among 17 other Platinum-resistant Ovarian Cancer trials with a reported enrollment target (67% lower). The listed sponsor is MacroGenics, which has 36 total studies on file at ClinicalTrials.gov.

The record links to 10 conditions, with Platinum-resistant Ovarian Cancer appearing as the primary indexed condition, and to 1 intervention - of which Lorigerlimab is the first listed.

NCT06730347 reports 16 study locations spanning 11 distinct geographic areas - top geographies include Other, Texas, California.

Frequently Asked Questions

What is clinical trial NCT06730347 about?

NCT06730347 is a clinical study titled "A Study of Lorigerlimab in Participants With Advanced Solid Tumors". Study CP-MGD019-03 is an open-label study of lorigerlimab in participants with platinum-resistant ovarian cancer (PROC) or clear cell gynecologic cancer (CCGC). Approximately 60 participants will be enrolled. The study will assess the efficacy and safety of lorigerlimab in participants with PROC or ...

What is the current status of trial NCT06730347?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2025-05-01. Estimated completion is 2027-08.

What conditions does trial NCT06730347 study?

This clinical trial studies the following conditions: Platinum-resistant Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Clear Cell Adenocarcinoma of Ovary, Clear Cell Adenocarcinoma of Vulva.

What interventions are being tested in trial NCT06730347?

The interventions under investigation include: Lorigerlimab (BIOLOGICAL).

Who is sponsoring clinical trial NCT06730347?

This trial is sponsored by MacroGenics, which has 36 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06730347 being conducted?

This trial has 16 study locations across California, Louisiana, Michigan, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Platinum-resistant Ovarian Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Platinum-resistant Ovarian Cancer

All registered trials for this condition

Platinum-Resistant Fallopian Tube Carcinoma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.